Global Amyloid-Beta and Tau-Targeted Alzheimer's Disease Therapeutics Market Strategic Research Report

The global amyloid-beta and tau-targeted Alzheimer's disease therapeutics market represents one of the most commercially consequential frontiers in modern neuroscience, valued at approximately USD 8.4 billion in 2024. This market encompasses a rapidly maturing pipeline of disease-modifying therapies—including anti-amyloid monoclonal antibodies, tau aggregation inhibitors, beta-secretase (BACE) inhibitors, and gamma-secretase modulators—designed to address the underlying neuropathological hallmarks of Alzheimer's disease rather than merely managing symptomatic progression. The approval of lecanemab (Leqembi) by the U.S. FDA in 2023 and donanemab's subsequent regulatory review marked an inflection point, transforming decades of largely unsuccessful clinical programs into a commercially viable therapeutic category. With an estimated 55 million people living with dementia globally, and Alzheimer's disease accounting for roughly 60–70% of all cases, the addressable patient population is unprecedented in scale and urgency.

Three principal forces are shaping the market's trajectory toward a projected CAGR of approximately 22.4% through 2032. First, the regulatory validation of amyloid clearance as a meaningful surrogate endpoint has materially de-risked late-stage development, encouraging both large pharmaceutical companies and well-capitalized biotechs to progress combination amyloid-tau programs. Second, the expansion of amyloid PET imaging and cerebrospinal fluid biomarker diagnostics—now increasingly supplemented by blood-based plasma p-tau217 assays—is broadening the eligible patient population by enabling earlier and more accessible diagnosis, a prerequisite for therapeutics whose efficacy is maximal in the pre-symptomatic or early symptomatic stages. Third, payers in the United States, European Union, and Japan are beginning to establish reimbursement frameworks that, while restrictive, provide a commercial pathway that was entirely absent five years ago. Constraining this outlook is the persistent challenge of amyloid-related imaging abnormalities (ARIA), a serious adverse event profile that demands intensive radiological monitoring infrastructure, limiting real-world uptake particularly in community neurology settings.

This report delivers a comprehensive commercial and scientific assessment of the amyloid-beta and tau-targeted Alzheimer's therapeutics market across the 2025–2032 forecast period. It covers market sizing, segmentation by therapeutic modality and disease stage application, regional and country-level forecasts, competitive landscape analysis, pipeline intelligence, and strategic company profiles for all major participants. Corporate strategy teams evaluating entry or expansion in the neurology space, investment analysts assessing biotech valuations, M&A advisors modeling acquisition targets within the Alzheimer's therapeutic ecosystem, and procurement managers at payer and hospital-system level will find actionable, data-anchored intelligence throughout this report.